SWOG clinical trial number
SWOG-9035
Randomized Trial of Adjuvant Immunotherapy with an Allogeneic Melanoma Vaccine for Patients with Intermediate Thickness, Node Negative Malignant Melanoma (T3N0M0), Phase III.
100% Accrual
Accrual
100%
Closed
100% Accrual
Accrual
100%
Published
Abbreviated Title
Randomized Trial of Adjuvant Immunotherapy with an Allogeneic Melanoma Vaccine for Patients with Intermediate Thickness, Node Negative Malignant Melanoma (T3N0M0), Phase III.
2004
Significant impact of HLA class I allele expression on outcome in melanoma patients treated with an allogeneic melanoma cell lysate vaccine. Final analysis of SWOG-9035.
VK Sondak;J Sosman;JM Unger;PY Liu;J Thompson;R Tuthill;R Kempf;L Flaherty Proc of the American Society of Clinical Oncology 23:707 (#7501)
2003
HLA D3(7) confers a poor prognosis in intermediate thickness (1.5-4.0mm) melanoma: serotyping of 553 patients on SWOG 9035.
JA Sosman;J Unger;JE Lee;P Liu;L Flaherty;VK Sondak Proc of the American Society of Clinical Oncology 22:710(#2856)
Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: melacine
VK Sondak;JA Sosman Seminars in Cancer Biology 13(6):409-415
2002
Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: Overall results of a randomized trial of the Southwest Oncology Group
VK Sondak;PY Liu;RJ Tuthill;RA Kempf;JM Unger;JA Sosman;JA Thompson;GR Weiss;BG Redman;JG Jakowatz;RD Noyes;LE Flaherty Journal of Clinical Oncology 20(8):2058-2066
Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: Impact of HLA class I antigen expression on outcome.
JA Sosman;JM Unger;PY Liu;LE Flaherty;MS Park;RA Kempf;JA Thompson;PI Terasaki;VK Sondak Journal of Clinical Oncology 20(8):2067-2075
HLA-A2 and/or HLA-C3 expression defines a subset of T3N0 melanoma patients with improved overall survival from melacine vaccine: an updated analysis of SWOG 9035.
JA Sosman;JM Unger;PY Liu;R Kempf;L Flaherty;J Thompson;VK Sondak Proc of the American Society of Clinical Oncology 21:340a(#1359)
2001
Significant impact of HLA classI alleles on outcome in T3NO melanoma patients treated with melacine (MEL): an allogeneic melanoma cell lysate vaccine: prospective analysis of Southwest Oncology Group (SWOG)-9035.
JA Sosman;JM Unger;PY Liu;L Flaherty;R Kempf;J Thompson;V Sondak Proc of the American Society of Clinical Oncology 20:351a(#1402)
2000
Adjuvant therapy with an allogeneic tumor vaccine in T3N0M0 melanoma (SWOG-9035)
VK Sondak;PY Liu;RJ Tuthill;RA Kempf;JM Unger;JA Sosman;JA Thompson;GR Weiss;BG Redman;LE Flaherty Proc of the Melanoma at the Millennium :79
SWOG-9035: adjuvant therapy of intermediate-thickness node-negative melanoma with an allogeneic tumor vaccine.
VK Sondak;PY Liu;RJ Tuthill;RA Kempf;JM Unger;JA Sosman;JA Thompson;GR Weiss;BG Redman;JG Jakowatz;RD Noyes;LE Flaherty Journal of Immunotherapy 23(5):600
Class I HLA serotyping in T3NO melanoma patients entered onto SWOG 9035: a phase III trial of melacine TM (allogeneic tumor lysate vaccine) vs observation.
JA Sosman;JM Unger;PY Liu;L Flaherty;J Thompson;VK Sondak Journal of Immunotherapy 23(5):605
1997
Adjuvant therapy for melanoma.
VK Sondak;JA Wolfe Current Opinion in Oncology 9:189-204